Low grade gliomas are invasive brain tumors that are difficult to completely 48 resect neurosurgically. They often recur following resection and progress, resulting in 49 death. Although previous studies have shown that specific germline variants increase the 50 risk of tumor formation, no previous study has screened many germline variants to 51 identify variants predictive of survival in glioma patients. In this study, we present an 52 approach to identify the small fraction of prognostic germline variants from the pool of 53 over four million variants that we variant called in The Cancer Genome Atlas whole 54 exome sequencing and RNA sequencing datasets. We identified two germline variants 55 that are predictive of poor patient outcomes by Cox regression, controlling for eleven 56 covariates. rs61757955 is a germline variant found in the 3' UTR of GRB2 associated 57 with increased KRAS signaling, CIC mutations, and 1p/19q co-deletion. rs34988193 is a 58 germline variant found in the tumor suppressor gene ANKDD1a that causes an amino 59 acid change from lysine to glutamate. This variant was found to be predictive of poor 60 prognosis in two independent low grade glioma datasets and is predicted to be within the 61 top 0.06% of deleterious mutations across the human genome. The wild type residue is 62 conserved in all 22 other species with a homologous protein. 63
Introduction 70
Grade II and grade III (low grade) gliomas are primary brain tumors that are 71 derived from glial cells and include astrocytomas and oligodendrogliomas. They are most 72 commonly found in the cerebral hemispheres. They are highly invasive and therefore 73 difficult to completely resect neurosurgically without significant patient morbidity. 74
Following surgery, patients are typically treated with chemotherapy and radiation, though 75 these tumors typically recur or progress to grade IV gliomas and are fatal. 1 1p/19q co-deletion status, telomerase reverse transcriptase (TERT) promoter mutation 82 status, MGMT promoter methylation, TP53 mutation status, and ATRX mutation status 83 may be used to molecularly characterize gliomas. 1, 3 The availability of genomic data 84 from patient glioma samples from groups such as The Cancer Genome Atlas (TCGA), the 85 Chinese Glioma Genome Atlas (CGGA), and the Ivy Glioblastoma Atlas Project has 86 substantially contributed to our understanding of these tumors. 4,5 87
Many studies have utilized these datasets to identify gene expression signatures, 88 microRNA expression patterns, somatic mutation status, and imaging characteristics that 89 are predictive of survival in low grade gliomas. [6] [7] [8] While studies have shown that 90 germline mutations can increase an individual's susceptibility for specific cancers, 9-12 91 including a recent study that identified 853 pathogenic or likely pathogenic germline 92 variants found in 8% of 10,389 cancer patients, 13 no study has comprehensively screened 93 all of the germline variants in a given cancer type to discover the prognostic variants in 94 that cancer type. Although germline mutations have been shown to be prognostic in 95 breast cancer 14 and medulloblastoma 9 in genes that have been well-characterized in the 96 context of these cancers, these variants were not identified using an unbiased approach 97 that screened a large number of germline variants. Identifying prognostic germline 98 variants is challenging due to the limited effect size of germline variants, the large 99 number of germline variants, and confounding clinical factors that may be associated 100 with germline variants. Here we present a novel methodology for identifying prognostic 101 germline variants and report two germline variants that we have found to be associated 102 with survival in low grade glioma patients. The raw sequencing data from the Chinese Glioma Genome Atlas patients was 114 downloaded using accession number SRP027383 from the Sequence Read Archive. 115
Clinical information for these patients was downloaded directly from the project's 116 website (http://www.cgga.org.cn/). 117
Variant Calling 118
Variant calling was performed on the TCGA low grade glioma whole exome 119 sequenced normal blood samples (WXS normal), whole-exome sequenced tumor samples 120 (WXS tumor), and RNA sequenced tumor samples (RNA tumor) using VarDict 17 on 121 CGC. The VarDict settings were set at default except for requiring mapping quality 122 greater than 30, base quality greater than 25, a minimum of 3 variant reads, minimum 123 allele frequency of 5%, and the removal of duplicate reads. We compiled a list of all of 124 the unique variants and ran 'samtools 18 depth' on all sequencing files requiring a 125 mapping quality greater than 30. We determined the status of each variant in each patient 126 from the three datasets (WXS normal sample, WXS tumor sample, and RNA tumor 127 sample). The variant status at positions with fewer than ten reads for a given patient was 128 changed to unknown. We used the WXS tumor samples to insert variant calls into the 129
We used annovar 19 to determine the allele frequencies of the variants called by 138
VarDict as listed in gnomAD (http://gnomad.broadinstitute.org/). We calculated the allele 139 frequency of the variants in our study using the following formula: 140
The R package GGally (https://cran.r-project.org/web/packages/GGally/index.html) was 143 used to calculate the correlation between the four variant call sets and to display their 144 correlations with each other. Only variants with an allele frequency of greater than 5% in 145 gnomAD and found in 15 or more of the TCGA low grade glioma patients were tested for 146 an association with survival by Cox regression. 147
Because we used the WXS tumor and RNA tumor samples to fill in missing 148 variant calls, we evaluated whether somatic mutations were affecting the validity of our 149 results. We first determined the percentage of variants called in the WXS tumor sample 150 that were somatic mutations. To do this, we downloaded the set of somatic mutations 151 generated by the TCGA Research Network. 20 We then calculated the number of somatic 152 mutations called in each patient in this variant call set and divided that number by the 153 total number of variants called in that patient's WXS normal sample. To assess whether 154 somatic mutations were affecting the integrity of our results, we counted the number of 155 times that a somatic mutation called by the TCGA Research Network overlapped with the 156 set of germline variants that we were testing for an association with survival. 157
Since we used the RNA tumor sample to fill in missing variant calls, we evaluated 158 whether RNA editing was having a significant impact on our analysis. To do this, we 159 downloaded the set of over 2.5 million known RNA editing sites from a rigorously 160 annotated database of RNA editing sites, RADAR. 21 We counted the number of times 161 that the germline variants that we were testing for an association with survival overlapped 162 with any of the known 2.5 million RNA editing sites. 163
Principal Component Analysis 164
In order to calculate principal components that could separate patients on the basis 165 of race, we used PLINK 22 to create a pruned set of germline variants to avoid bias from 166 variants in linkage disequilibrium. Pruning was performed using a window size of 50 167 variants and a variance inflation factor of 2. These variants were used to calculate 168 principal components using base R. 169
Cox Regression and Receiver Operator Characteristic Curves 170
Lasso in the R package glmnet 23 was run on 17 covariates ( Table 1) . Information 171 about patient age, gender, tumor location, grade, treatment site, and TP53 mutation status 172 was acquired from the TCGA data portal, while data for patient somatic mutation count, 173 percent aneuploidy, TERT expression, IDH mutation status, 1p/19q co-deletion status, 174
MGMT promoter methylation status, and chromosome 7 gain with chromosome 10 loss 175 status was acquired from Ceccarelli et. al. 16 The principal components were calculated as 176 described above. 11 of these 17 covariates were selected for inclusion in the final model 177 for survival prediction. The R packages survival 24 and survminer 25 were used to run Cox 178 regression and create Kaplan-Meier curves. For each minor allele, we our model tested 179 whether the minor allele was associated with a difference in survival outcomes with 180 respect to the reference allele. False discovery rate correction was performed through 181
Bonferroni correction. 182
Receiver operator characteristic (ROC) curves were created and evaluated using 183 the survivalROC (https://cran.r-184 project.org/web/packages/survivalROC/survivalROC.pdf) and pROC (https://cran.r-185 project.org/web/packages/pROC/pROC.pdf) R packages. In order to test whether 186 rs61757955 significantly improves the survival model consisting of the eleven covariates 187 selected by Lasso, we compared the two ROC curves using the bootstrap method with 188 1000 iterations. We also used this bootstrapping approach to determine whether 189 ANKDD1a expression levels, GRB2 expression levels, rs61757955, and rs34988193 190 together improve the survival model with respect to the eleven covariates selected by 191
Lasso. 192
RNA-Sequencing Data Processing 193
We downloaded the HTSeq FPKM quantification files for each patient from the 194 Genomic Data Commons data portal. We only used gene quantification files from 195 primary tumor samples as part of this analysis. Replicate samples from a single patient 196 were averaged. 197
Variant Correlation to Covariates and Somatic Mutations 198
In order to test for associations between the germline variants and genomic and 199 histological tumor characteristics, we divided patients based on their germline variant 200 status. We used the Wilcoxon rank-sum test to test for significant differences in each of 201 the continuous variables between patients with and without a given variant. We used 202
Fisher's exact test to test for differences in each of the discrete variables using a similar 203 approach. Somatic mutation calls were downloaded from Ellrott et. al. 20 204
Gene Set Enrichment Analysis 205
Gene set enrichment analysis (GSEA) of mRNA changes associated with 206 rs61757955 and rs34988193 was performed by dividing the patients into two groups for 207 each variant based on whether or not they had the reference allele at the position of the 208 variant. For each germline variant, we calculated the log fold change for all genes 209 expressed greater than one fragment per kilobase per million mapped reads (FPKM) 210 between patients with the variant and without the variant. For each gene, fold change was 211 calculated by dividing the median expression of the gene in patients with the variant by 212 the median expression of the gene in patients without the variant. We used the log fold 213 change to rank the genes from greatest log fold change to smallest log fold change. This 214 file was used as input for GSEA. 26 215
Variant Annotation 216
In order to identify deleterious mutations, we annotated all variants by combined 217 annotation dependent depletion (CADD) scores and only analyzed the variants predicted 218 to be within the top 0.1% of all deleterious variants (CADD > 30). 27 This led us to 219 identify rs34988193 in ANKDD1a as a potentially deleterious variant predictive of 220 survival. Because rs34988193 causes an amino acid change from positively charged 221 lysine to negatively charged glutamate, we ran a BLASTp 222 (httpps://blast.ncbi.nlm.nih.gov/Blast.cgi) search so that we could determine how many 223 species have a protein homologous to ANKDD1a and how consistently the wild type 224 lysine residue was conserved. We identified homologous sequences in 22 other species. 225
These sequences were aligned using ClustalW in MEGA. 28 We also annotated this 226 variant with its PhyloP score. 29 Because the crystal structure for ANKDD1a was not 227 available, we downloaded the predicted model for this protein from Modbase 228 (https://modbase.compbio.ucsf.edu/modbase-cgi/index.cgi) and calculated the Gribskov 229 score using prophecy on EMBOSS. 30 We retrieved linked variants from Ensembl using 230 the population of Utah residents with Northern and Western European ancestry which is 231 demographically similar to the TCGA low grade glioma patient population. 232
Results 233

Identification of High Quality Germline Variants 234
Our variant calling pipeline is shown in Figure 1 . Briefly, we used the variant 235 caller VarDict on Cancer Genomics Cloud to identify variants from whole exome 236 sequencing (WXS) and RNA sequencing samples in about 500 low grade glioma 237 patients. In total, we found 4,453,701 unique variants. We used 'samtools depth' to 238 determine the sequencing depth at each of these variants for each patient and changed the 239 variant status to 'unknown' for patients with sequencing coverage less than 10 reads at a 240 given position. We created a set of combined variant calls by using the WXS and RNA 241 tumor samples to fill in unknown values in the whole exome sequenced normal samples 242 that resulted from having a sequencing coverage of less than 10 reads at a given position. 243
This approach increased our sample size and enabled us to include many more variants in 244 our analysis than if we had solely used variant calls from the whole exome sequenced 245 normal blood samples. Ultimately, this left us with four sets of variants -WXS normal, 246 WXS tumor, RNA tumor, and a combined set that resulted from merging the other three 247 variant call sets, giving preference to the WXS normal and then WXS tumor variant calls. 248
We used the combined variant call set when testing variants for an association with 249 survival. We only tested variants found in 15 or more low grade glioma TCGA patients 250 and listed in gnomAD as having an allele frequency of greater than 5%. 251
Tumor Variant Calls are not Significantly Affected by Somatic Mutations or RNA 252
Editing After Filtering 253
Because we used sequencing data from the WXS tumor and RNA tumor samples 254 to fill in missing calls in the WXS normal samples, we evaluated our variant calls for 255 contributions from somatic mutations and RNA editing. We first showed that the 256 majority of variant calls in the tumor sample are germline variant calls. To do this, we 257 counted the number of somatic mutations called by the TCGA Research Network's 258 analysis in each patient and divided that number by the number of variants that we called 259 in the WXS normal sample. 20 The median number of somatic mutations called per patient 260 was 39. The median number of variants called in the WXS normal sample was 95,794. 261
We therefore estimated that over 99.9% of variants called in the WXS tumor sample 262 consisted of germline variants and that the percentage of somatic mutations in the WXS 263 tumor sample across all patients was quite small (Figure S1 ). Because somatic mutations 264 rarely occur at the same position, we suspected that the number of somatic mutations 265 included in our study was extremely small since we limited our analysis to variants found 266 in 15 or more of the low grade glioma patients and found in gnomAD with an allele 267 frequency of greater than 5%. Indeed, only one of the 196,022 variants that we tested 268 overlapped with a somatic mutation. This somatic mutation occurred in only a single 269 patient (Table S1 ). Ultimately, we did not find any evidence to suggest that somatic 270 mutations were impacting the quality of our analysis. 271
We next determined whether RNA editing was affecting our analysis by 272 downloading the 2.5 million known RNA editing sites from the rigorously annotated 273 RNA editing database, RADAR. 21 Only 215 of the 196,022 variants that we tested were 274 located at a position that overlapped with a known RNA editing site. We did not find any 275 of these variants to be prognostic as part of our analysis. We therefore did not find any 276 empirical evidence to suggest that somatic mutations or RNA editing impacted our 277 findings ( Table S1) . 278
Finally, we established that our four variant call sets (WXS normal, WXS tumor, 279
RNA tumor, and combined) were concordant with each other by calculating the allele 280 frequency of each variant called in the four sets and demonstrating a very strong 281 correlation between all pairs of variants (r > 0.98 for all pairs, Figure S2 ). To further 282 evaluate the quality of our variants calls, we calculated the frequency of each allele and 283 compared it to the frequency of these alleles as listed in gnomAD. Our alleles frequencies 284
were well correlated with gnomAD (r > 0.93 for all four variant sets, Table S2 ). As 285 expected, the distribution of allele frequencies is negatively skewed as the majority of the 286 identified variants are rare ( Figure S2) . We used the variants from the WXS normal 287 samples to determine the principal components. As expected, these principal components 288 effectively separate patients on the basis of reported race (Figure S3) . 289
Identification of 271 Prognostic Germline Variants that are Independent of Clinical 290
Covariates 291
In order to identify clinically relevant germline variants, we restricted our analysis 292 to variants found in at least 15 patients in the TCGA dataset and found in gnomAD with 293 an allele frequency of greater than five percent. This restricted our analysis to 196,022 294 testable variants (Figure 2A) . In order to reduce the risk of identifying variants that are 295 prognostic because they are confounded by other covariates known to be associated with 296 survival, we used the machine learning algorithm Lasso to determine which of 17 297 covariates should be controlled for in our Cox regression model. Lasso regression was 298 useful in the screening of these 17 covariates because it penalizes models based on the 299 number of coefficients, allowing for the elimination of less predictive coefficients from 300 the model. The algorithm selected 10 covariates known to be associated with differences 301 in survival in low grade glioma (age, somatic mutation count, percent aneuploidy, 302 histological subtype of astrocytoma, tumor grade, treatment site, IDH mutation status, 303 1p/19q co-deletion status, MGMT promoter methylation status, chromosome 7 304 gain/chromosome 10 loss status) along with the third principal component that we 305 calculated ( Table 1) 196,022 variants one at a time, controlling for these 11 covariates, to identify germline 313 variants predictive of survival. 314
We identified 271 germline variants that are predictive of survival (p < 0.001) 315 (Figure 2A) . As is the case with germline variants in general, the majority of these 316 germline variants are found in protein-coding genes (Figure 2B) , are located in introns 317 ( Figure 2C) , and are single nucleotide polymorphisms (Figure 2D) . Most single 318 nucleotide polymorphisms are transitions (Figure 2E) . 319
The Germline Variant rs61757955 in GRB2 is Associated with Poor Prognosis 320
We identified two germline variants that are highly predictive of survival after 321 false discovery rate correction (FDR < 0.10) ( Figure 3A, Table 2A ). rs61757955 results 322 in a mutation in the 3' UTR of Growth Factor Receptor Bound Protein 2 (GRB2) and is 323 associated with a poor prognosis (p=7.08E-10, hazard ratio(HR)=20.4, Figure 3B , Table  324 2A). To determine whether rs61757955 enhances the survival model compared to the 325 eleven clinical covariates alone, we calculated a risk score for each patient using a Cox 326 regression model with rs61757955 and the other 11 covariates and a risk score using the 327 11 covariates alone. Using these risk scores, we determined the rate at which a patient 328 would be correctly labeled as alive or dead at 7 years with a given false positive rate to 329 create a receiver operator characteristic curve. The increased area under the curve 330 suggests that rs61757955 enhances the survival model compared to the eleven clinical 331 covariates alone (p=0.0489, Figure 3C) . The allele frequency of rs61757955 is close to 332 0% according to the 1000 Genomes Project 31 in the Chinese population and, as expected, 333 did not show up in the Chinese Glioma Genome Atlas. We also found rs28672782, a 334 germline variant found in the intron of BRSK2, to be associated with a favorable 335 prognosis, though the testable sample size for this variant was small and the maximum 336 follow up for patients with this variant was only three years. Therefore, we did not 337 investigate this variant further (Figure S4, Table 2A ). 338
In order to test whether rs61757955 in GRB2 is associated with an increased risk 339 of other genomic abnormalities, we separated patients on the basis of this variant to see if 340 there was a difference in the incidence of the genomic or histological variables ( Table 3) . 341
We found this variant to be associated with an increased incidence of 1p/19q co-deletions 342 (p=0.038). Because 1p/19q co-deletions are frequently seen in Capicua transcriptional 343 repressor (CIC) mutated gliomas 32 and CIC aberrations are known to be a driver in low 344 grade glioma tumorigenesis, 33 we tested whether there was a difference in the incidence 345 of CIC mutations in patients with this variant. 38% of patients with this variant had CIC 346 mutated gliomas, whereas only 16% of patients without the variant had a CIC mutation 347 (p=0.0168, Table 3 ). Although the incidence of oligodendrogliomas was elevated in 348 patients with the variant compared to patients without the variant, consistent with reports 349 from the literature that 1p/19q co-deletions and CIC mutations are enriched in 350 oligodendrogliomas, 32 this difference was not statistically significant (p=0.475). Since 351 rs61757955 is in a non-coding region, we also tested whether this variant is associated 352 with differences in gene expression. We separated patients based on their variant status 353 and calculated the log fold change of each gene between patients with the variant and 354 patients without the variant. This data was used as the input for gene set enrichment 355 analysis (GSEA). We found rs61757955 to be associated with increased KRAS signaling 356 (FDR=0.015) (Figure 3D) . 357
Because we only have whole exome sequencing and RNA sequencing data from 358
The Cancer Genome Atlas, we do not know whether the upregulation of genes in the 359 KRAS signaling pathway and the increased incidence of CIC mutations and 1p/19q 360 deletions are due to this variant or a linked variant in a regulatory region that we would 361 be able to analyze with whole genome sequencing data. Therefore, we identified the four 362 other variants that are genetically linked to rs61757955 in the European population, the 363 population which is most similar to the TCGA low grade glioma patient population 364 (Table S3 ). These variants did not pass the criteria to be included within the 196,022 365 testable variants that we had identified at the beginning of this study but could become 366 useful in the future. 367
rs34988193 is a Deleterious Germline Variant Present in ANKDD1a Associated with 368
Poor Outcomes 369
In order to identify prognostic variants that are predicted to be deleterious due to 370 effects on the encoded protein, we repeated our analysis but restricted it to only variants 371 with a combined annotation dependent depletion (CADD) score greater than 30 and 372 expression greater than one FPKM on average. 81 variants met this criteria. These 373 variants correspond to the top 0.1% of deleterious mutations as predicted by this scoring 374 system. We found the germline variant rs34988193 in the tumor suppressor gene 375
ANKDD1a to be associated with poor prognosis in the TCGA dataset (p=0.001, 376 HR=1.73, FDR < 0.10, Figure 4A-B, Table 2B ). Because this variant is found in both 377 the European and Asian populations, we were able to test whether this variant is also 378 predictive of survival in the independent Chinese Glioma Genome Atlas (CGGA) dataset. 379
We found this variant to be predictive of survival in the CGGA dataset and we found the 380 hazard ratio that we calculated in CGGA to be very similar to the hazard ratio calculated 381 in the TCGA dataset (p=0.0743, HR=1.79, Figure 4C , Table 2B ). rs34988193 is not 382 linked with any other variant in the European population. We did not find any enriched 383 pathways after performing gene set enrichment analysis and this variant was not 384 associated with differences of any of the genomic or histological variables (Table S4) . between ankyrin repeats nine and ten (Figure 4D) . This variant has a CADD score of 32 390 and is therefore predicted to be in the top 0.06% of deleterious mutations across the 391 human genome. We performed a BLASTp search using the ANKDD1a protein sequence 392 to identify homologous sequences in 22 other species. We aligned these sequences using 393
ClustalW and found that this lysine residue is conserved in all 22 of these species (Figure  394   4E) . The PhyloP score at this position is 8.42, suggesting that evolution is occurring 395 much more slowly than expected at this residue assuming no selection pressure. We 396 determined the position-specific profile Gribskov's score for a lysine to glutamate amino 397 acid change at this position using the multiple sequencing alignment from 23 species to 398 be 15 to 3, suggesting that this variant is highly unfavorable. 399
Combined Model Predicts Survival Better Than Clinical Covariates Alone 400
As a result of this analysis, we found the germline variants rs61757955 in the 3' 401 variants. In this study, we have developed a novel method that can be used to identify 420 prognostic germline variants and we have used that method to identify two variants that 421 are predictive of survival in the TCGA dataset. The germline variant rs61757955 in 422 GRB2 is not found in the Asian population and so could not be confirmed in an 423 independent dataset. In contrast, the germline variant rs34988193 in ANKDD1a is found 424 in both the European and Asian populations, and remarkably, was found to be prognostic 425 with very similar hazard ratios in both the TCGA and CGGA datasets. 426
Studies of germline variants using TCGA datasets typically solely utilize the 427
WXS normal blood samples. 13, 38 One major disadvantage to this approach is that it limits 428 the analysis to genes within the capture regions of the whole exome sequencing kits used 429 by the study. 4 In this study, we combined the information from both the whole exome 430 sequencing and RNA sequencing datasets for a given patient to identify germline variants 431 outside of the whole exome sequencing capture region. Our approach had the added 432 benefit of providing us with more information for a given variant for variants with low 433 sequencing depth in the whole exome sequencing datasets. We do not believe that this 434 approach significantly affected the accuracy of our variant calls because the allele 435 frequencies calculated from the RNA sequencing dataset were well correlated with the 436 allele frequencies from gnomAD and with the allele frequencies calculated from the 437 whole exome sequencing datasets. We showed that somatic mutations and RNA editing 438 did not affect the integrity of our finding. Only one somatic mutation in a single patient 439 overlapped with the 196,022 variants that we tested in our analysis and only 215 of the 440 196,022 variants that we tested overlapped with the 2.5 million known RNA editing sites. 441
We did not find any of these variants to be predictive of survival. Instead, we feel that the 442 increased sample size resulting from the additional sequencing coverage greatly 443 outweighs any effect that somatic mutations or RNA editing had on our results. 444
We next needed to devise an approach to using these germline variants in a Cox 445 regression model. We first had to decide how to deal with the absence of a variant in the 446 variant call file. The variant could be absent because the patient was wild type for that 447 allele or because the sequencing depth at that position was too low to make the variant 448 call. We therefore determined the sequencing depth of each variant at each position so 449 that we could exclude patients with low sequencing depths for the testing of specific 450 variants. Testing a large number of variants increased the probability of a variant being 451 significant solely because it was confounded with another significant variable. To avoid 452 this issue, we tested each variant while controlling for 11 other covariates that we found 453 to be predictive of survival. In this study, we found rs61757955 to be associated with 454 differences in 1p/19q co-deletion status. By including the 1p/19q co-deletion as a 455 covariate in our model, we were able to estimate the effect of rs61757955 independent 456 from the 1p/19q co-deletion status and the other ten covariates. 457 GRB2 is a signal transduction adaptor protein that plays an oncogenic role in a 458 variety of cancers. 39-42 GRB2 plays an important role in the RAS/RAF/ERK pathway. Its 459 SH2 domain binds the phosphotyrosine of activated growth factor receptor, while its two 460 SH3 domains bind the guanine nucleotide exchange factor son of sevenless (SOS) 461 protein, resulting in SOS recruitment to the plasma membrane and subsequent RAS 462 activation. RAS binds and activates the kinase RAF, which phosphorylates the kinase 463
MEK. MEK phosphorylates and activates extracellular signal-regulated kinase (ERK) 464
which transmits the signal to transcription factors in the nucleus. This results in cell 465 proliferation. 43 We found the variant rs61757955 located in the 3' UTR of GRB2 to be 466 associated with poor prognosis in glioma patients. Separating patients on the basis of this 467 variant revealed that the KRAS signaling pathway is upregulated in patients with this 468 variant. As described above, GRB2 plays a well-characterized role in this pathway. 43 We 469 also found this variant to be associated with an increased incidence of CIC mutations and 470 1p/19q co-deletions. CIC is a known driver of low grade glioma pathogenesis. 33 471
Mutations in CIC are common in oligodendrogliomas and are associated with poor 472 prognosis. 4,32 Although patients with rs61757955 variant exhibited an elevation in the 473 incidence of oligodendrogliomas which we expected given the increased incidence of 474 CIC mutations and 1p/19q co-deletions, 32 this difference was not statistically significant. 475 It is possible that this germline variant or the four other germline variants that it is linked 476 with increase a patient's risk for oligodendrogliomas with the CIC mutation and 1p/19q 477 co-deletion. 478
In this study, we were only able to study variants in the whole exome or RNA 479 sequencing data. Although it is possible that the 3' UTR of GRB2 has regulatory activity 480 or affects GRB2 protein translation efficiency, it is also possible that one of the variants 481 that rs61757955 is linked to regulates the KRAS signaling pathway. None of the four 482 linked variants are in the protein coding sequence of GRB2 so that if they upregulate 483 RAS activity, like the rs61757955, they likely do so by regulating the expression of 484 GRB2. While recent large-scale sequencing studies have published patient whole genome 485 sequences, 44 this data is not yet available for gliomas. We will be able to apply our 486 approach to variants in regulatory regions in the future to specifically identify these 487 prognostic variants when whole genome sequencing data for gliomas is available. Our 488 inability to further study this variant in the CGGA dataset due to this variant being rare in 489
Asian populations is a limitation of this study which could be addressed in the future with 490 the availability of additional glioma sequencing datasets. This result also suggests that the 491 clinical usefulness of specific germline variants is dependent on the frequency of that 492 germline variant in the population. 493
ANKDD1a is a tumor suppressor gene that has been shown to inhibit cell 494 autophagy and induce apoptosis in glioblastoma multiforme (GBM). It directly interacts 495 with and upregulates FIH1, resulting in inhibition of HIF1α activity and decreased 496
HIF1α half-life. This induces apoptosis in GBM cell lines in hypoxic microenvironments. 497
Hypermethylation of this gene is common in GBM and leads to decreased ANKDD1a 498 expression and increased cell proliferation. 45 We found the germline variant rs34988193, 499 located at the end of the ninth of ten ankyrin repeat domains in this protein, to be 500 associated with a poor prognosis in low grade glioma patients in both the TCGA and 501 CGGA datasets. The hazard ratio independently calculated using the two datasets is 502 remarkably similar. The wild type lysine residue is conserved in all 22 species with a 503 homologue to ANKDD1a and this position has a high PhyloP score. This variant is 504 predicted to be within the top 0.06% of deleterious mutations in the human genome by 505 CADD score 27 because it causes a change from a positively charged lysine residue to a 506 negatively charged glutamic acid residue in the loop of this ankyrin repeat. Ankyrin 507 repeats are common domains known for their involvement with protein-protein 508 interactions. 46, 47 Previous studies have suggested that mutations in the loops of ankyrin 509 repeats may disrupt protein-protein interactions. [48] [49] [50] The change from a positively to 510 negatively charged amino acid resulting from the germline variant rs34988193 in the loop 511 of ANKDD1a may disrupt ANKDD1a's protein interaction partners and could explain the 512 poor prognosis associated with this variant seen in two independent datasets. Given the 513 amino acid change, further studies involving rs34988193 in ANKDD1a could be directed 514 towards experimentally determining whether or not this variant alters ANKDD1a's 515 protein-protein interactions. 516 rs61757955 in GRB2 and rs34988193 in ANKDD1a could also be used to enhance 517 predictions made by survival models clinically, as we found that these variants are 518 significant predictors of prognosis even after controlling for eleven covariates. The 519 prognostic effect of rs34988193 in ANKDD1a seems to be fairly reliable, as we found 520 that this variant had a similar hazard ratio in both the TCGA and CGGA datasets. Our 521 approach could be used in the future to identify sets of germline variants that together 522 enhance the predictions made by survival models, though the current number of low 523 grade glioma sequencing samples is small relative to the large number of possible 524 combinations of germline variants. Focused studies on particular sets of genes or 525 pathways could potentially get around this low sample size problem by drastically 526 limiting the number of variants studied. We believe that this study provides researchers 527 with an effective approach to identifying biologically significant germline variants and 528 provides clinicians with germline variants that could enhance currently existing survival 529 models. 530
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